HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB)

PHASE2TerminatedINTERVENTIONAL
Enrollment

87

Participants

Timeline

Start Date

December 26, 2020

Primary Completion Date

March 27, 2024

Study Completion Date

April 17, 2024

Conditions
Hepatitis B, Chronic
Interventions
BIOLOGICAL

HepTcell

Intramuscular injection

DRUG

Placebo

Intramuscular injection

Trial Locations (21)

20246

Univesritätsklinikum Hamburg-Eppendorf, Hamburg

28046

Hospital Universitario La Paz, Madrid

41014

Hospital Nuestra Señora De Valme, Seville

46014

Consorcio Hospital General Universitario De Valencia, Valencia

46026

Hospital Universitari I Politècnic La Fe, Valencia

60590

Goethe University Hospital, Frankfurt am Main

64131

Kansas City Research Institute, Kansas City

73071

Central Sooner Research, Oklahoma City

92840

Paragon Rx Clinical, Garden Grove

94063

Stanford University Department of Medicine, Redwood City

95128

San Jose Gastroenterology Institute, San Jose

T2N 4Z6

University of Calgary Liver Unit - Heritage Medical Research Clinic, Calgary

T6G 2G3

University of Alberta Hospital, Edmonton

K1H 8L6

The Ottawa Hospital, Ottawa

M5G 2C4

Toronto Centre for Liver Disease (TCLD), Toronto General Hospital, UHN, Toronto

M6H 3M1

Toronto Liver Centre, Toronto

08028

Hospital Clínic De Barcelona, Barcelona

08035

Hospital Universitari Vall D'Hebron, Barcelona

SW17 0RE

St. Georges University of London, London

W2 1NY

St. Mary's Hospital, London

NG7 2UH

Queens Medical Center, Nottingham

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Altimmune, Inc.

INDUSTRY